Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Hydroxychloroquine  COVID-19 treatment studies for HCQ  C19 studies: HCQ  HCQ   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality -17% Improvement Relative Risk Death/ICU -78% Hospitalization -45% c19hcq.org Trefond et al. HCQ for COVID-19 PrEP Is pre-exposure prophylaxis with HCQ beneficial for COVID-19? Retrospective 262 patients in France Higher death/ICU (p=0.21) and hospitalization (p=0.12), not stat. sig. Trefond et al., Revue du Rhumatisme, doi:10.1016/j.rhum.2021.09.004 Favors HCQ Favors control
Effet d’un traitement par hydroxychloroquine prescrit comme traitement de fond de rhumatismes inflammatoires chroniques ou maladies auto-immunes systémiques sur les tests diagnostiques et l’évolution de l’infection à SARS CoV-2: étude de 871 patients
Trefond et al., Revue du Rhumatisme, doi:10.1016/j.rhum.2021.09.004 (date from earlier preprint)
Trefond et al., Effet d’un traitement par hydroxychloroquine prescrit comme traitement de fond de rhumatismes inflammatoires.., Revue du Rhumatisme, doi:10.1016/j.rhum.2021.09.004 (date from earlier preprint)
Jan 2021   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Retrospective 71 chronic HCQ patients compared with 191 matched controls, analyzing only those with a highly suspected or confirmed diagnosis of COVID-19. No significant difference was found in outcomes, however matching failed with extreme confounding - 77.5% of HCQ patients with systemic autoimmune diseases vs. 21.5% of control patients.
Other research shows that the risk of COVID-19 for systemic autoimmune disease patients is much higher overall, Ferri et al. show OR 4.42, p<0.001 [Ferri]. This study is excluded in the after exclusion results of meta analysis: not fully adjusting for the different baseline risk of systemic autoimmune patients; significant unadjusted confounding possible; excessive unadjusted differences between groups.
risk of death, 16.6% higher, RR 1.17, p = 0.80, treatment 4 of 68 (5.9%), control 12 of 183 (6.6%), adjusted per study, odds ratio converted to relative risk.
risk of death/ICU, 78.2% higher, RR 1.78, p = 0.21, treatment 8 of 71 (11.3%), control 18 of 191 (9.4%), adjusted per study, odds ratio converted to relative risk.
risk of hospitalization, 44.9% higher, RR 1.45, p = 0.12, treatment 24 of 71 (33.8%), control 53 of 191 (27.7%), adjusted per study, odds ratio converted to relative risk.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Trefond et al., 27 Jan 2021, retrospective, France, peer-reviewed, 21 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperHCQAll
Abstract: Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. Journal Pre-proof Effet d’un traitement par hydroxychloroquine prescrit comme traitement de fond de rhumatismes inflammatoires chroniques ou maladies auto-immunes systémiques sur les tests diagnostiques et l’évolution de l’infection à SARS CoV-2: étude de 871 patients Ludovic Trefond Elodie Drumez Marc Andre Nathalie Costedoat-Chalumeau Raphaèle Seror Mathilde Devaux Emmanuelle Dernis Yannick Dieudonne Soumaya El Mahou Aurelia Lanteri Isabelle Melki Viviane Queyrel Mathilde Roumier Jean Schmidt Thomas Barnetche Thierry Thomas Patrice Cacoub Alexandre Belot Olivier Aumaitre Christophe Richez Eric Hachulla, FAI2R/SFR/SNFMI/SOFREMIP/CRI/IMIDIATE consortium et contributeurs PII: S1169-8330(21)00248-9 DOI: https://doi.org/doi:10.1016/j.rhum.2021.09.004 Reference: REVRHU 5360 To appear in: Revue du rhumatisme Please cite this article as: Trefond L, Drumez E, Andre M, Costedoat-Chalumeau N, Seror R, Devaux M, Dernis E, Dieudonne Y, Mahou SE, Lanteri A, Melki I, Queyrel V, Roumier M, Schmidt J, Barnetche T, Thomas T, Cacoub P, Belot A, Aumaitre O, Richez C, Hachulla E, Effet d’un traitement par hydroxychloroquine prescrit comme traitement de fond de rhumatismes inflammatoires chroniques ou maladies auto-immunes systémiques sur les tests diagnostiques et l’évolution de l’infection à SARS CoV-2: étude de 871 patients, Revue du rhumatisme (2021), doi: https://doi.org/10.1016/j.rhum.2021.09.004 This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. © 2020 Published by Elsevier. Effet d’un traitement par hydroxychloroquine prescrit comme traitement de fond de rhumatismes inflammatoires chroniques ou maladies auto-immunes systémiques sur les tests diagnostiques et l’évolution de l’infection à SARS CoV-2 : étude de 871 patients Ludovic Trefond,1 Elodie Drumez,2 Marc Andre,1 Nathalie Costedoat-Chalumeau,3 Raphaèle Seror,4 Mathilde Devaux,5 Emmanuelle Dernis,6 Yannick Dieudonne,7 Soumaya El Mahou,8 Aurelia Lanteri,9 Isabelle Melki,10 Viviane Queyrel,11 Mathilde Roumier,12 Jean Schmidt,13 Thomas Barnetche,14 Thierry Thomas,15 Patrice Cacoub,16 Alexandre Belot,17 Olivier Aumaitre,1 Christophe Richez,14 Eric Hachulla,18 FAI2R/SFR/SNFMI/SOFREMIP/CRI/IMIDIATE consortium et..
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit